Tango Therapeutics, Inc

TNGXNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

168.4M

on 2026-06-30, from 106.7M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

S-3 of 2025-11-21. Not read yet. S-3 ↗

$400.0M

Leerink Partners, agreement of 2025-11-21. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-11 is not read yet.

Cash

28.2 quarters

$1.01B on 2026-06-30 ÷ $36.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-06-09	Public offering incl. 1.83M pre-funded	20,000,062	$30.00	$600.0M	424B5 ↗